PharmacyCodes



Moexiprilum [INN-Latin] en es it fr

Moexiprilum [INN-Latin] Brand names, Moexiprilum [INN-Latin] Analogs

Moexiprilum [INN-Latin] Brand Names Mixture

  • No information avaliable

Moexiprilum [INN-Latin] Chemical_Formula

C66H83N17O13

Moexiprilum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic2/nafarelin.htm

Moexiprilum [INN-Latin] fda sheet

Moexiprilum [INN-Latin] msds (material safety sheet)

Moexiprilum_[INN-Latin] MSDS

Moexiprilum [INN-Latin] Synthesis Reference

No information avaliable

Moexiprilum [INN-Latin] Molecular Weight

1321.6344 g/mol

Moexiprilum [INN-Latin] Melting Point

No information avaliable

Moexiprilum [INN-Latin] H2O Solubility

No information avaliable

Moexiprilum [INN-Latin] State

Solid

Moexiprilum [INN-Latin] LogP

No information avaliable

Moexiprilum [INN-Latin] Dosage Forms

Liquid; Metered-dose (aerosol)

Moexiprilum [INN-Latin] Indication

For treatment of gonadotropin-dependent precocious puberty in children of both sexes and for the treatment of endometriosis.

Moexiprilum [INN-Latin] Pharmacology

Nafarelin is a potent agonistic analog of gonadotropin-releasing hormone (GnRH). At the onset of administration, nafarelin stimulates the release of the pituitary gonadotropins, LH and FSH, resulting in a temporary increase of gonadal steroidogenesis. Repeated dosing abolishes the stimulatory effect on the pituitary gland. Twice daily administration leads to decreased secretion of gonadal steroids by about 4 weeks; consequently, tissues and functions that depend on gonadal steroids for their maintenance become quiescent. After nafarelin therapy is discontinued, pituitary and ovarian function normalize and estradiol serum concentrations increase to pretreatment levels. Recurrences of endometriosis are frequent after cessation of any hormonal therapy and after surgery that leaves the ovaries and/or uterus intact.

Moexiprilum [INN-Latin] Absorption

Rapidly absorbed into the systemic circulation after intranasal administration. Bioavailability from a 400 µg dose averaged 2.8% (range 1.2 to 5.6%). Not absorbed after oral administration.

Moexiprilum [INN-Latin] side effects and Toxicity

In experimental animals, a single subcutaneous administration of up to 60 times the recommended human dose (on a µg/kg basis, not adjusted for bioavailability) had no adverse effects. At present, there is no clinical evidence of adverse effects following overdosage of GnRH analogs.

Moexiprilum [INN-Latin] Patient Information

Moexiprilum [INN-Latin] Organisms Affected

Humans and other mammals